Burden of disease

Pneumococcal pneumonia | Invasive pneumococcal disease (IPD) | Vaccination rates

Vaccination rates

The majority of eligible adults with a risk condition did not receive a pneumococcal vaccine in 2022¹

Pneumococcal vaccination rates of eligible adults 50+, 2022¹

Pneumococcal Vaccine Rates: 37% of Adults Ages 50-64 (Previous Risk-Based Recommendation); 70% of Adults Ages 65+ (Previous Age-Based Recommendation)

Based on 2022 CDC BRFSS data.

9 out of 10 adults aged 50-64 years who were diagnosed with IPD or hospitalized with pneumococcal pneumonia had at least one risk condition.¹

The CDC lowering the age-based recommendations to 50+ was based on several factors, including the potential to improve vaccination rates and ease of implementation.¹

How can I help address the burden?

Learn about IPD case coverage and how PCV recommendations could affect patients aged 50+.

Get the facts

Share with health care professionals

BRFSS, Behavioral Risk Factor Surveillance System; CDC, Centers for Disease Control and Prevention; IPD, invasive pneumococcal disease.

Reference:

Kobayashi M, Leidner AJ, Gierke R, et al. Expanded recommendations for use of pneumococcal conjugate vaccines among adults aged ≥50 years: recommendations of the Advisory Committee on Immunization Practices — United States, 2024. MMWR Morb Mortal Wkly Rep. 2025;74(1):1-8. doi:10.15585/mmwr.mm7401a1

Indications

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for:

active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.
active immunization for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in individuals 18 years of age and older.

The indication for the prevention of pneumonia caused by S. pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B is approved under accelerated approval based on immune responses as measured by opsonophagocytic activity (OPA). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Select Safety Information

Do not administer CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) to individuals with a history of a severe allergic reaction (eg, anaphylaxis) to any component of CAPVAXIVE or to diphtheria toxoid.

Individuals with altered immunocompetence, including those receiving immunosuppressive therapy, may have a reduced immune response to CAPVAXIVE.

The most commonly reported (>10%) solicited adverse reactions in individuals 18 through 49 years of age who received CAPVAXIVE were: injection-site pain (73.1%), fatigue (36.0%), headache (27.5%), myalgia (16.4%), injection-site erythema (13.8%), and injection-site swelling (13.3%).

The most commonly reported (>10%) solicited adverse reactions in individuals 50 years of age and older who received CAPVAXIVE were: injection-site pain (41.2%), fatigue (19.7%), and headache (11.0%).

Vaccination with CAPVAXIVE may not protect all vaccine recipients.

Before administering CAPVAXIVE, please read the accompanying Prescribing Information. The Patient Information also is available.

Indications Indications

Select Safety Information Select Safety Information